Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 4/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 2/20 | 0.31 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8249720 | 0.94 | PLK1 (0.36) | LMNAPLK1PPARGAGTR2AGTR1 | |
| SCHEMBL12884207 | 0.90 | PTGER1 (0.36) | LMNAALDH1A1TDP1PLK1HTT | |
| SCHEMBL8241502 | 0.88 | HTT (0.41) | LMNAPLK1HTTSMN1; SMN2KDM4E | |
| SCHEMBL8252428 | 0.88 | KDR (0.32) | LMNAALDH1A1TDP1PLK1PPARG | |
| SCHEMBL8242381 | 0.82 | TLR7 (0.35) | PPARGAGTR2AGTR1 | |
| SCHEMBL8251911 | 0.81 | PLK1 (0.34) | PLK1PPARGAGTR2AGTR1KDR | |
| SCHEMBL8284704 | 0.81 | LMNA (0.40) | LMNAALDH1A1TDP1HTTSMN1; SMN2 | |
| SCHEMBL8286263 | 0.80 | CSF1R (0.44) | LMNAALDH1A1TDP1HTTSMN1; SMN2 | |
| SCHEMBL12884184 | 0.79 | HTT (0.43) | LMNAALDH1A1HTTSMN1; SMN2KDM4E | |
| SCHEMBL17521663 | 0.78 | CSF1R (0.45) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896450-B1 | 2-SUBSTITUTED BENZIMIDAZOLES | JANSSEN R & D IRELAND (IE) | 2012-08-15 | — | — | EP | disclosed |
| US-7884215-B2 | 2-substituted benzimidazoles | JANSSEN SCIENCES IRELAND UC (IE) | 2011-02-08 | — | — | US | disclosed |
| US-20100092426-A1 | 2-SUBSTITUTED BENZIMIDAZOLES | JANSSEN SCIENCES IRELAND UC (IE) | 2010-04-15 | — | — | US | disclosed |
| WO-2006136563-A1 | 2-SUBSTITUTED BENZIMIDAZOLES | TIBOTEC PHARMACEUTICALS LTD (IE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092426-A1 | 2-SUBSTITUTED BENZIMIDAZOLES | HTR4, HRH4, HTR3C | LMNA 1628/4885ALDH1A1 563/4885TDP1 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.